COMMUNIQUÉS West-GlobeNewswire

Form 8 (DD) - Albert Stroucken
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - Susan Kilsby
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - David Ginsburg
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Avivagen Announces Proposed Extension of Warrants
20/12/2018
OTTAWA, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, today announced that it will be [...]
Eton Pharmaceuticals Reports Third Quarter Results and Business Update
20/12/2018
Licensed High-Value Injectable Product Candidate Successfully Completed Initial Public Offering DEER PARK, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical [...]
ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions
20/12/2018
Call Scheduled for 9am Eastern Time RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and [...]
Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™
20/12/2018
PEDMARK TM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. RESEARCH TRIANGLE PARK [...]
Genmab Announces European Commission Approval of DARZALEX® (daratumumab) Split Dosing Regimen
20/12/2018
Media Release Split dosing regimen approved by European Commission Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days Approval supported by data from EQUULEUS ( [...]
Herb Names Maverick Technology Solutions’ ROSINBOMB™ Rocket the Best Portable Rosin Press
20/12/2018
The “Voice of Cannabis Culture” Names the Rocket the Best Press to Take Anywhere and Everywhere RENO, Nev., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Maverick Technology Solutions (OTC:MVRK) innovator and manufacturer of the [...]
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
20/12/2018
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a [...]
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
20/12/2018
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a [...]
Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
20/12/2018
– Global SAVANNAH study of savolitinib / Tagrisso ® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among the most frequent mechanisms of acquired resistance t o [...]
Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
20/12/2018
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all development costs of [...]
Rule 2.9 Announcement
20/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 20 December 2018 [...]
AroCell signs distribution agreement with Eurobio Scientific in France
20/12/2018
AroCell AB (publ) announced today that a distribution agreement has been signed with the French company Eurobio Scientific, for distribution of AroCell TK 210 ELISA in France and Switzerland. AroCell TK 210 ELISA [...]
PCI Biotech: Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer
20/12/2018
Oslo (Norway), 20 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced preliminary confirmation that the safety endpoint has been reached in the Phase I extension study [...]
Grant of Warrants
20/12/2018
December 20, 2018 Announcement no. 26 Grant of Warrants In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of [...]
Novartis announces new CEO of Oncology Business Unit
20/12/2018
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D., currently President, [...]
MannKind Announces Pricing of $40 Million Public Offering
20/12/2018
WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and [...]

Pages